These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1778877)

  • 1. Increased dosing requirements for amikacin in burned children.
    Kopcha RG; Fant WK; Warden GD
    J Antimicrob Chemother; 1991 Nov; 28(5):747-52. PubMed ID: 1778877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin population pharmacokinetics among paediatric burn patients.
    Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
    Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
    Labaune JM; Bleyzac N; Maire P; Jelliffe RW; Boutroy MJ; Aulagner G; Putet G
    Biol Neonate; 2001 Aug; 80(2):142-7. PubMed ID: 11509814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside dosing in burn patients using first-dose pharmacokinetics.
    Hollingsed TC; Harper DJ; Jennings JP; Morris SE; Saffle JR
    J Trauma; 1993 Sep; 35(3):394-8. PubMed ID: 8371297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The necessity of increased doses of amikacin in burn patients.
    Zaske DE; Sawchuk RJ; Strate RG
    Surgery; 1978 Nov; 84(5):603-8. PubMed ID: 715674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns].
    Yang RH; Rong XZ; Zhang T; Hua R
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):172-4. PubMed ID: 17355928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant.
    Kenyon CF; Knoppert DC; Lee SK; Vandenberghe HM; Chance GW
    Antimicrob Agents Chemother; 1990 Feb; 34(2):265-8. PubMed ID: 2327775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin pharmacokinetics in pediatric patients with malignancy.
    Cleary TG; Pickering LK; Kramer WG; Culbert S; Frankel LS; Kohl S
    Antimicrob Agents Chemother; 1979 Dec; 16(6):829-32. PubMed ID: 533263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
    Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
    Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized pharmacokinetic versus standard dosing of amikacin: a comparison of therapeutic outcomes.
    Dillon KR; Dougherty SH; Casner P; Polly S
    J Antimicrob Chemother; 1989 Oct; 24(4):581-9. PubMed ID: 2693431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure.
    Nayir A; Sirin A; Emre S; Eti S; Yeşilbek T
    Turk J Pediatr; 1995; 37(2):111-6. PubMed ID: 7597761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data.
    Petersen PO; Wells TG; Kearns GL
    Dev Pharmacol Ther; 1991; 16(4):203-11. PubMed ID: 1782838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.